View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 11, 2021updated 12 Jul 2022 11:22am

Galapagos and Gilead Sciences to halt Phase III IPF trials

Galapagos and Gilead Sciences have announced the decision to discontinue the ISABELA Phase III clinical studies of ziritaxestat (GLPG1690) in patients with idiopathic pulmonary fibrosis (IPF).

Galapagos and Gilead Sciences have announced the decision to discontinue the ISABELA Phase III clinical studies of ziritaxestat (GLPG1690) in patients with idiopathic pulmonary fibrosis (IPF).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Discovered by Galapagos, ziritaxestat is an investigational autotaxin inhibitor. In July 2019, Gilead in-licensed ex-European rights to ziritaxestat and began sharing the Phase III development costs.

The latest move is based on the recommendation by the Independent Data Monitoring Committee (IDMC). Following a regular review of unblinded data, the committee noted that ziritaxestat’s benefit-risk profile no longer supported the continuation of these studies.

Galapagos chief medical officer Dr Walid Abi-Saab said: “We are very disappointed not to be able to bring a novel medication to patients suffering from such a devastating disease with high unmet need.

“We intend to learn from this data in our continued commitment to developing therapies in IPF and fibrosis.”

Investigators are being notified of the discontinuation of the studies and the participants will be informed to stop the investigational treatment.

The ISABELA Phase III programme has two trials that have been identically designed: ISABELA 1 & 2, intending to enrol a total of 1,500 IPF patients.

Patients continued on their standard of care background treatment and randomly received either a once-daily dose of ziritaxestat 200mg or 600mg or placebo.

The rate of decline of forced vital capacity until week 52 was the primary endpoint.

All clinical trials with ziritaxestat, including the long-term extension of the Phase IIa NOVESA trial in systemic sclerosis, will be discontinued.

Last May, Gilead Sciences and Galapagos reported positive top-line results from the Phase IIb/III SELECTION clinical trial of filgotinib for the treatment of moderately to severely active ulcerative colitis (UC).

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena